Kyverna Therapeutics Statistics
Total Valuation
KYTX has a market cap or net worth of $110.52 million. The enterprise value is -$201.93 million.
Important Dates
The next estimated earnings date is Tuesday, March 18, 2025, before market open.
| Earnings Date | Mar 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KYTX has 43.17 million shares outstanding. The number of shares has increased by 5,987.19% in one year.
| Current Share Class | 43.17M |
| Shares Outstanding | 43.17M |
| Shares Change (YoY) | +5,987.19% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | 2.26% |
| Owned by Institutions (%) | 39.32% |
| Float | 22.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.50, with a Debt / Equity ratio of 0.03.
| Current Ratio | 10.50 |
| Quick Ratio | 10.38 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -741.60 |
Financial Efficiency
Return on equity (ROE) is -59.58% and return on invested capital (ROIC) is -38.48%.
| Return on Equity (ROE) | -59.58% |
| Return on Assets (ROA) | -34.79% |
| Return on Invested Capital (ROIC) | -38.48% |
| Return on Capital Employed (ROCE) | -38.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.15M |
| Employee Count | 96 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.07% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -91.07% |
| 50-Day Moving Average | 3.19 |
| 200-Day Moving Average | 6.17 |
| Relative Strength Index (RSI) | 34.81 |
| Average Volume (20 Days) | 296,200 |
Short Selling Information
The latest short interest is 3.07 million, so 7.12% of the outstanding shares have been sold short.
| Short Interest | 3.07M |
| Short Previous Month | 2.79M |
| Short % of Shares Out | 7.12% |
| Short % of Float | 13.72% |
| Short Ratio (days to cover) | 6.92 |
Income Statement
| Revenue | n/a |
| Gross Profit | -96.15M |
| Operating Income | -120.14M |
| Pretax Income | n/a |
| Net Income | -110.66M |
| EBITDA | -119.05M |
| EBIT | -120.14M |
| Earnings Per Share (EPS) | -$3.99 |
Full Income StatementBalance Sheet
The company has $321.59 million in cash and $9.14 million in debt, giving a net cash position of $312.45 million or $7.24 per share.
| Cash & Cash Equivalents | 321.59M |
| Total Debt | 9.14M |
| Net Cash | 312.45M |
| Net Cash Per Share | $7.24 |
| Equity (Book Value) | 302.71M |
| Book Value Per Share | 7.01 |
| Working Capital | 294.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$95.75 million and capital expenditures -$2.01 million, giving a free cash flow of -$97.76 million.
| Operating Cash Flow | -95.75M |
| Capital Expenditures | -2.01M |
| Free Cash Flow | -97.76M |
| FCF Per Share | -$2.26 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |